A new approach for prediction of tumor sensitivity to targeted drugs based on functional data

被引:27
作者
Berlow, Noah [1 ]
Davis, Lara E. [2 ]
Cantor, Emma L. [2 ]
Seguin, Bernard [3 ]
Keller, Charles [2 ]
Pal, Ranadip [1 ]
机构
[1] Texas Tech Univ, Dept Elect & Comp Engn, Lubbock, TX 79409 USA
[2] Oregon Hlth & Sci Univ, Dept Pediat, Pape Family Pediat Res Inst, Portland, OR 97201 USA
[3] Colorado State Univ, Flint Anim Canc Ctr, Ft Collins, CO 80523 USA
来源
BMC BIOINFORMATICS | 2013年 / 14卷
基金
美国国家科学基金会;
关键词
MUTATIONS; CHEMOSENSITIVITY; ENCYCLOPEDIA; THERAPY; CANCERS; PATHWAY;
D O I
10.1186/1471-2105-14-239
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Background: The success of targeted anti-cancer drugs are frequently hindered by the lack of knowledge of the individual pathway of the patient and the extreme data requirements on the estimation of the personalized genetic network of the patient's tumor. The prediction of tumor sensitivity to targeted drugs remains a major challenge in the design of optimal therapeutic strategies. The current sensitivity prediction approaches are primarily based on genetic characterizations of the tumor sample. We propose a novel sensitivity prediction approach based on functional perturbation data that incorporates the drug protein interaction information and sensitivities to a training set of drugs with known targets. Results: We illustrate the high prediction accuracy of our framework on synthetic data generated from the Kyoto Encyclopedia of Genes and Genomes (KEGG) and an experimental dataset of four canine osteosarcoma tumor cultures following application of 60 targeted small-molecule drugs. We achieve a low leave one out cross validation error of < 10% for the canine osteosarcoma tumor cultures using a drug screen consisting of 60 targeted drugs. Conclusions: The proposed framework provides a unique input-output based methodology to model a cancer pathway and predict the effectiveness of targeted anti-cancer drugs. This framework can be developed as a viable approach for personalized cancer therapy.
引用
收藏
页数:20
相关论文
共 38 条
  • [1] ANDREASSEN A, 1993, CANCER RES, V53, P468
  • [2] The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
    Barretina, Jordi
    Caponigro, Giordano
    Stransky, Nicolas
    Venkatesan, Kavitha
    Margolin, Adam A.
    Kim, Sungjoon
    Wilson, Christopher J.
    Lehar, Joseph
    Kryukov, Gregory V.
    Sonkin, Dmitriy
    Reddy, Anupama
    Liu, Manway
    Murray, Lauren
    Berger, Michael F.
    Monahan, John E.
    Morais, Paula
    Meltzer, Jodi
    Korejwa, Adam
    Jane-Valbuena, Judit
    Mapa, Felipa A.
    Thibault, Joseph
    Bric-Furlong, Eva
    Raman, Pichai
    Shipway, Aaron
    Engels, Ingo H.
    Cheng, Jill
    Yu, Guoying K.
    Yu, Jianjun
    Aspesi, Peter, Jr.
    de Silva, Melanie
    Jagtap, Kalpana
    Jones, Michael D.
    Wang, Li
    Hatton, Charles
    Palescandolo, Emanuele
    Gupta, Supriya
    Mahan, Scott
    Sougnez, Carrie
    Onofrio, Robert C.
    Liefeld, Ted
    MacConaill, Laura
    Winckler, Wendy
    Reich, Michael
    Li, Nanxin
    Mesirov, Jill P.
    Gabriel, Stacey B.
    Getz, Gad
    Ardlie, Kristin
    Chan, Vivien
    Myer, Vic E.
    [J]. NATURE, 2012, 483 (7391) : 603 - 607
  • [3] Benassi MS, 1999, INT J CANCER, V84, P489, DOI 10.1002/(SICI)1097-0215(19991022)84:5<489::AID-IJC7>3.0.CO
  • [4] 2-D
  • [5] Involvement of p21Waf1/Cip1 in protein kinase C alpha-induced cell cycle progression
    Besson, A
    Yong, VW
    [J]. MOLECULAR AND CELLULAR BIOLOGY, 2000, 20 (13) : 4580 - 4590
  • [6] High-throughput genotyping in osteosarcoma identifies multiple mutations in phosphoinositide-3-kinase and other oncogenes
    Choy, Edwin
    Hornicek, Francis
    MacConaill, Laura
    Harmon, David
    Tariq, Zeeshan
    Garraway, Levi
    Duan, Zhenfeng
    [J]. CANCER, 2012, 118 (11) : 2905 - 2914
  • [7] Molecularly targeted Therapy: Have the floodgates opened?
    Druker, BJ
    [J]. ONCOLOGIST, 2004, 9 (04) : 357 - 360
  • [8] Translation of the Philadelphia chromosome into therapy for CML
    Druker, Brian J.
    [J]. BLOOD, 2008, 112 (13) : 4808 - 4817
  • [9] Targeting targeted therapy
    Green, MR
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (21) : 2191 - 2193
  • [10] Can we rationally design promiscuous drugs?
    Hopkins, AL
    Mason, JS
    Overington, JP
    [J]. CURRENT OPINION IN STRUCTURAL BIOLOGY, 2006, 16 (01) : 127 - 136